Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest.
暂无分享,去创建一个
Hung Chiang | Chih-Yi Hsu | Chiung-Ru Lai | Donald Ming-Tak Ho | D. Ho | Chih‐Yi Hsu | H. Chiang | Ching-Fen Yang | I-Ting Yu | Ching-Fen Yang | Chiung‐Ru Lai | I. Yu | Chiung-Ru Lai
[1] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[2] E. Frenkel,et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays , 2000, Journal of clinical pathology.
[3] E. Kay,et al. C-erbB-2 immunostaining: problems with interpretation. , 1994, Journal of clinical pathology.
[4] Persons Dl,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .
[5] D. Larsimont,et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. , 2000, American journal of clinical pathology.
[6] D. Persons,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[7] E. Frenkel,et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. , 2001, American journal of clinical pathology.
[8] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Vecchione,et al. Correlation between ploidy status, Erb-B2 and p53 immunohistochemical expression in primary breast carcinoma. , 1995, Analytical and quantitative cytology and histology.
[10] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[11] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] John J Spinelli,et al. HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.
[13] I. Ellis,et al. Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.
[14] B. Everitt,et al. Statistical methods for rates and proportions , 1973 .
[15] A. Gown,et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Ridolfi,et al. HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.
[17] M. Trudeau,et al. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[18] H A Lehr,et al. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. , 2001, American journal of clinical pathology.
[19] James N Ingle,et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. , 2002, Mayo Clinic proceedings.
[20] D. Birnbaum,et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation , 1994, The Journal of pathology.
[21] T. Brenner,et al. Biotechnology Update: First MAb Approved for Treatment of Metastatic Breast Cancer , 1999 .
[22] J. Wisecarver. HER-2/neu testing comes of age. , 1999, American journal of clinical pathology.
[23] H. Tsuda,et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis , 2001, Pathology international.
[24] A. Vincent-Salomon,et al. Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma , 2000, Modern Pathology.
[25] B. Jasani,et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. , 2002, American journal of clinical pathology.
[26] J. Fletcher,et al. HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.
[27] S. Schnitt,et al. Current status of HER2 testing: caught between a rock and a hard place. , 2001, American journal of clinical pathology.
[28] D. Slamon,et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.
[29] T. Grogan,et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] T. Brenner,et al. First MAb approved for treatment of metastatic breast cancer. , 1999, Journal of the American Pharmaceutical Association.
[31] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[32] J. Fleiss,et al. Statistical methods for rates and proportions , 1973 .
[33] J. Ingle,et al. Increased HER2 with U.S. Food and Drug Administration-approved antibody. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.